Skip to main content

Table 1 Patient demographics by PHBR score (< 0.5 vs. ≥ 0.5) (N = 83)

From: MHC-I genotype and tumor mutational burden predict response to immunotherapy

Variable

Group

N (82)

PHBR < 0.5 (N = 32)

PHBR ≥ 0.5 (N = 51)

Relative risk (95% CI)1

P value2

Sex

Male

46

22 (48%)

24 (52%)

1.77 (0.96–3.26)

0.07

Female

37

10 (27%)

27 (73%)

Ethnicity

Caucasian

71

27 (38%)

44 (62%)

0.91 (0.44–1.90)

> 0.99

Others3

12

5 (42%)

7 (58%)

Age4 (years)

< 60

17

6 (35%)

11 (65%)

0.90 (0.44–1.82)

> 0.99

≥ 60

66

26 (39%)

40 (61%)

Tumor type

Head and neck SCC

9

4 (44%)

5 (56%)

1.18 (0.54–2.58)

0.73

Others

74

28 (38%)

46 (62%)

NSCLC

26

7 (27%)

19 (73%)

0.61 (0.31–1.23)

0.16

Others

57

25 (44%)

32 (56%)

Cutaneous SCC

10

7 (70%)

3 (30%)

2.04 (1.22–3.42)

0.04

Others

73

26 (34%)

48 (66%)

Others5

38

14 (37%)

24 (63%)

0.92 (0.53–1.60)

0.82

Head and neck SCC, NSCLC, and cutaneous SCC

45

18 (40%)

27 (60%)

TMB6 (mutations/mb)

< 50

65

21 (32%)

44 (68%)

0.49 (0.28–0.83)

0.048

≥ 50

12

8 (67%)

4 (33%)

< 20

56

18 (32%)

38 (68%)

0.61 (0.35–1.07)

0.12

≥ 20

21

11 (52%)

10 (48%)

< 10

38

11 (29%)

27 (71%)

0.63 (0.34–1.15)

0.16

≥ 10

39

18 (46%)

21 (54%)

PD-1/L1 Therapy

Monotherapy

66

26 (39%)

40 (61%)

1.12 (0.55–2.27)

> 0.99

Combination

17

6 (35%)

11 (65%)

Overall benefit rate

SD ≥ 6 months/PR/CR7

36

17 (47%)

19 (53%)

1.45 (0.84–2.49)

0.25

Others

46

15 (33%)

31 (67%)

PD

32

7 (22%)

25 (78%)

0.45 (0.22–0.91)

0.02

Others

51

25 (49%)

26 (51%)

  1. 1Relative risk for PHBR < 0.5
  2. 2Calculated using Fisher’s exact test
  3. 3Others: African American (N = 2), Asian (N = 4), Hispanic (N = 5), and unknown (N = 1)
  4. 4At time of initiation of treatment with immunotherapy
  5. 5Others: adrenal (N = 1), appendix (N = 4), basal cell carcinoma (N = 3), breast cancer (N = 6), cervical (N = 1), cholangiocarcinoma (N = 1), colorectal (N = 2), duodenal (N = 1), gastroesophageal (N = 5), glioblastoma (N = 2), thyroid (N = 1), prostate (N = 1), rectal squamous cell carcinoma (N = 1), renal cell carcinoma (N = 1), sarcoma (N = 3), urothelial (N = 4), and urethral squamous cell carcinoma (N = 1)
  6. 6TMB was performed on 77 patients
  7. 7One patient had SD, but had not reached to 6 months. Only 82 patients were evaluable for this comparison
  8. Abbreviations: CR complete response, HR hazard ratio, NR not reached to 50%, NSCLC non-small cell lung cancer, OS overall survival, PFS progression-free survival, PD progressive disease, PHBR Patient Harmonic-mean Best Rank, PR partial response, RR relative risk, SCC squamous cell carcinoma, SD stable disease, TMB tumor mutational burden